Os Therapies INC 10-Q quarterly reports

OS Therapies Inc. reported substantial Q2 2026 losses and a going concern warning, despite positive clinical trial results for its lead candidate OST-HER2.

OS Therapies Inc. reported its first quarter 2026 financial results, highlighting significant increases in research and development expenses and continued net losses, while advancing its OST-HER2 therapy towards regulatory submissions.

OS Therapies announced positive two-year survival data for its lead cancer therapy OST-HER2, while reporting increased losses and a going concern warning.

OS Therapies reported a significantly wider net loss in Q2 2025, driven by increased R&D and administrative costs, while securing new capital and advancing its lead cancer immunotherapy.

OS Therapies Incorporated announces its financial results for the quarter ended March 31, 2025, showcasing progress in its clinical trials and recent asset acquisitions.

OS Therapies reported its financial results for the third quarter of 2024, highlighting its recent IPO and ongoing clinical trial for Osteosarcoma.

OS Therapies Incorporated reported its financial results for the quarter ended June 30, 2024, noting a net loss but also highlighting its recent IPO and ongoing clinical trial for Osteosarcoma therapy.

OS Therapies Incorporated reported a net loss of $1.49 million for the first quarter of 2024, while continuing to advance its Osteosarcoma therapy and seek additional capital.